Literature DB >> 16328513

Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.

George Kontogeorgos1, Eva Horvath, Kalman Kovacs, Claire Coire, Ricardo V Lloyd, Bernd W Scheithauer, Harley S Smyth.   

Abstract

Treatment of patients with prolactin (PRL)-producing pituitary adenomas with dopamine agonists has proved successful for most cases. Dopamine agonists inhibit PRL secretion, suppress cell proliferation, and may induce apoptosis to adenoma cells. Dopamine agonists induce striking morphologic changes in the majority of treated PRL-producing adenomas. To date, these morphologic effects have been primarily described only after long-term treatment. To the best of our knowledge, no similar studies have investigated apoptotic alterations induced after short-term therapy. The purpose of this report is to describe the morphologic changes seen in PRL-producing adenomas after short-term dopamine agonist treatment. We present two cases of PRL-producing macroadenomas, both from male patients who received treatment with dopamine agonists, the first for 5 and the second for 8 days. In contrast to long-term treatment, no striking reduction of PRL immunoreactivity was noted. Slight stromal fibrosis was noted in case 1, which contained several cells all in late phase of apoptosis. In addition to typical apoptotic cells, numerous "dark" cells representing another common form of cell death were also noted. These novel findings represent characteristic features of short-term dopamine agonist treatment, which are not seen in long-term treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328513     DOI: 10.1007/s00401-005-1111-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

1.  Pituitary gland: can prolactinomas be cured medically?

Authors:  Mark E Molitch
Journal:  Nat Rev Endocrinol       Date:  2010-04       Impact factor: 43.330

2.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  The pseudocapsule surrounding a pituitary adenoma and its clinical significance.

Authors:  Xin Qu; Guangming Xu; Yuanming Qu; Tao Song
Journal:  J Neurooncol       Date:  2010-06-06       Impact factor: 4.130

4.  MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.

Authors:  George Kontogeorgos; Eleni Thodou; Mary Koutourousiou; Gregory Kaltsas; Andreas Seretis
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

5.  Remission of acromegaly following long-term therapy with cabergoline: report of two cases.

Authors:  Johan A Verhelst; Pascale J Abrams; Roger Abs
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?

Authors:  Etual Espinosa-Cárdenas; Miriam Sánchez-García; Claudia Ramírez-Rentería; Victoria Mendoza-Zubieta; Ernesto Sosa-Eroza; Moises Mercado
Journal:  Endocrine       Date:  2020-06-17       Impact factor: 3.633

Review 7.  Apoptosis: its role in pituitary development and neoplastic pituitary tissue.

Authors:  M F Guzzo; L R S Carvalho; M D Bronstein
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

8.  Bromocriptine therapy for the treatment of invasive prolactinoma: the single institute experience.

Authors:  Kyung Rae Cho; Kyung-Il Jo; Hyung Jin Shin
Journal:  Brain Tumor Res Treat       Date:  2013-10-31

9.  Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma.

Authors:  Cristiana Tanase; Radu Albulescu; Elena Codrici; Bogdan Calenic; Ionela Daniela Popescu; Simona Mihai; Laura Necula; Maria Linda Cruceru; Mihail Eugen Hinescu
Journal:  Onco Targets Ther       Date:  2014-12-22       Impact factor: 4.147

10.  Prolactin-producing pituitary adenoma with atypical spindle cell morphology: a case report.

Authors:  Ritsurou Inoue; Mikiko Aoki; Yoshihisa Matsumoto; Seiji Haraoka; Kiyoshi Kazekawa; Kazuki Nabeshima
Journal:  World J Surg Oncol       Date:  2015-07-31       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.